Skip to main content
Caplight Logo









Renerva, Inc.

Renerva, Inc.

Private
Pittsburgh, PennsylvaniaHealthcare & Life Scienceshttps://www.renerva.com/

Last Round

Grant

Sep 24, 2019

Total Funding Raised

$3.86M

Company Overview

Renerva, Inc. is a medical device company that develops and commercializes implantable technologies to improve peripheral nerve repair outcomes.

Sector

Healthcare & Life Sciences

Verticals

Medical Devices, Biotechnology, Clinical Trials

Business Model

B2B

Customer Profile

Hardware Sales, Government Contracts

AI Layer

Non-AI

Keywords

nerve capping deviceperipheral nerve injuryneuroma preventionimplantable deviceMedTechnerve repairbiodegradable implantamputee carenerve capchronic pain treatmentclinical-stage companybiomaterialsnerve conduitinjectable hydrogelInvestigational Device ExemptionIDE

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Renerva, Inc. Comparables

Compare Renerva, Inc. with similar companies based on industry and business-model similarity.

Renerva, Inc. comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Regenity Biosciences
79%
Neuraptive Therapeutics
78%
Axogen Inc
78%

Renerva, Inc. Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantSep 24, 2019
SeedApr 30, 2019
GrantDec 14, 2018

Key People

Founding team and executive leadership

Lorenzo Soletti

Co-Founder And CEO

Founding Team

Renerva, Inc. Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jan 19, 2026

    Monthly visitors increased 70% MoM.

  • Nov 13, 2025

    Monthly visitors grew 138% MoM, reaching 1.5K.

Renerva, Inc. Filings

Explore SEC and related filing metadata, where available.

Renerva, Inc. filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Renerva, Inc.'s valuation, stock price, and market status.

Is Renerva, Inc. a public or private company?

Renerva, Inc. is a private company.

What is the current stock price of Renerva, Inc.?

Renerva, Inc. is a private company with no public stock price. No recent secondary market data is available.

How much is Renerva, Inc. worth (valuation)?

Valuation information for Renerva, Inc. is not publicly available.

Can I buy Renerva, Inc. stock?

Renerva, Inc. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Renerva, Inc.'s last funding round?

Renerva, Inc.'s most recent funding round was Grant on September 24, 2019.

Who are the main investors in Renerva, Inc.?

Key investors in Renerva, Inc. include Keiretsu Forum, Chemical Angel Network, NIH RADx, University of Pittsburgh, U.S. Department of War.

Will Renerva, Inc. IPO soon?

No public IPO plans have been announced for Renerva, Inc..

How can I track Renerva, Inc. secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Renerva, Inc.'s secondary market activity and sign up for updates.

Firmographic Details

HeadquartersPittsburgh, Pennsylvania
Employee Range7
Year Founded2017
Last FundingSep 24, 2019

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?